Thymosin Alpha 1-RGDR (Tα1-RGDR)
Tα1-RGDR combines the immunomodulatory properties of Thymosin Alpha 1 with tumor-targeting RGDR sequence through a flexible GGGG linker. This 36-amino acid modified peptide binds selectively to integrin αvβ3 and Neuropilin-1 (NRP-1) receptors overexpressed on tumor cells and vascular endothelium.
The RGDR motif contains both the RGD integrin-binding sequence and a C-terminal R/KXXR/K motif for NRP-1 recognition. Research in mouse models shows Tα1-RGDR targets tumor tissue more efficiently than unmodified Tα1 while maintaining immune system activation through CD4+ and CD8+ T cell upregulation.
Studies demonstrate applications in non-small cell lung cancer, melanoma, and other solid tumor models where integrin αvβ3 expression is elevated.
For in vitro research applications only.
Specifications
- Sequence:
- Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-Gly-Gly-Gly-Gly-Arg-Gly-Asp-Arg
- Structure:
- Thymosin Alpha 1 (28 aa) + GGGG linker (4 aa) + RGDR targeting motif (4 aa)
- Total Amino Acids:
- 36 amino acids
- Molecular Formula:
- C167H279N49O67S (approximate)
- Molecular Weight:
- ~3821 g/mol
- Targeting Motifs:
- RGDR (integrin αvβ3 binding), C-terminal R/KXXR/K motif (NRP-1 binding)
- Synonyms:
- Thymosin Alpha 1-RGDR, Tα1-RGDR, Modified Thymosin Alpha 1
- Purity:
- ≥99% (HPLC)
- Solubility:
- Soluble in sterile water
- Storage Conditions:
- Store at ≤-20°C, tightly sealed, away from heat and moisture
- Physical Appearance:
- White lyophilized powder
- Shelf Life:
- 36 months from date of manufacture when stored properly
- Quality Verification:
- Third-party tested by certified laboratory
- Manufacturing Standard:
- USA-made, pharmaceutical-grade, GMP compliant
- Intended Application:
- In vitro research applications only



